Reata Pharmaceuticals, Inc. (NASDAQ:RETA) CAO Elaine Castellanos Sells 8,454 Shares

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) CAO Elaine Castellanos sold 8,454 shares of the company’s stock in a transaction dated Wednesday, June 9th. The shares were sold at an average price of $141.90, for a total transaction of $1,199,622.60. Following the transaction, the chief accounting officer now directly owns 16,092 shares of the company’s stock, valued at $2,283,454.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Elaine Castellanos also recently made the following trade(s):

  • On Monday, June 7th, Elaine Castellanos sold 1,546 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $146.75, for a total transaction of $226,875.50.
  • On Wednesday, May 26th, Elaine Castellanos sold 10,000 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $124.55, for a total transaction of $1,245,500.00.

RETA stock opened at $146.01 on Friday. Reata Pharmaceuticals, Inc. has a 1 year low of $76.34 and a 1 year high of $186.82. The business has a 50-day moving average of $104.95. The company has a market capitalization of $5.30 billion, a P/E ratio of -18.89 and a beta of 1.50.

Reata Pharmaceuticals (NASDAQ:RETA) last announced its earnings results on Thursday, May 6th. The company reported ($1.86) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.18) by $0.32. Reata Pharmaceuticals had a negative net margin of 3,092.54% and a negative return on equity of 88.44%. The business had revenue of $0.94 million during the quarter, compared to the consensus estimate of $1.43 million. During the same quarter last year, the firm earned ($0.89) earnings per share. The business’s revenue for the quarter was down 30.2% on a year-over-year basis. On average, equities research analysts anticipate that Reata Pharmaceuticals, Inc. will post -8.47 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Principal Financial Group Inc. increased its stake in shares of Reata Pharmaceuticals by 3.5% during the first quarter. Principal Financial Group Inc. now owns 9,015 shares of the company’s stock valued at $899,000 after purchasing an additional 306 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its stake in shares of Reata Pharmaceuticals by 5.5% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 43,320 shares of the company’s stock valued at $4,319,000 after purchasing an additional 2,264 shares in the last quarter. Squarepoint Ops LLC increased its stake in shares of Reata Pharmaceuticals by 204.2% during the first quarter. Squarepoint Ops LLC now owns 7,615 shares of the company’s stock valued at $759,000 after purchasing an additional 5,112 shares in the last quarter. Voloridge Investment Management LLC bought a new position in shares of Reata Pharmaceuticals during the first quarter valued at approximately $1,664,000. Finally, Point72 Asset Management L.P. increased its stake in shares of Reata Pharmaceuticals by 43.4% during the first quarter. Point72 Asset Management L.P. now owns 58,800 shares of the company’s stock valued at $5,862,000 after purchasing an additional 17,800 shares in the last quarter. 69.02% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Reata Pharmaceuticals in a research note on Monday, May 24th. They set a “buy” rating and a $236.00 price objective for the company. Citigroup upped their price objective on shares of Reata Pharmaceuticals from $234.00 to $244.00 and gave the company a “buy” rating in a research note on Thursday, May 20th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price target on shares of Reata Pharmaceuticals from $234.00 to $244.00 and gave the stock a “buy” rating in a research note on Thursday, May 20th. Finally, Barclays assumed coverage on shares of Reata Pharmaceuticals in a research note on Monday, April 26th. They issued an “overweight” rating and a $155.00 price target for the company. Seven analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $229.22.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.

Featured Article: Momentum Investing

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.